Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA1 | P02708 | 2/20 | 0.50 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.50 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.50 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.50 |
| ▸ | EGFR | P00533 | 4/20 | 0.44 |
| ▸ | TYMS | P04818 | 4/20 | 0.44 |
| ▸ | LTA4H | P09960 | 4/20 | 0.44 |
| ▸ | VDR | P11473 | 4/20 | 0.44 |
| ▸ | SRC | P12931 | 4/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.44 |
| ▸ | CTSK | P43235 | 4/20 | 0.44 |
| ▸ | AR | P10275 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7503669 | 0.90 | CHRNA7 (0.50) | CHRNA1CHRNA7CHRNB2CHRNA4EGFR | |
| SCHEMBL7508741 | 0.79 | CHRNA1 (0.55) | CHRNA1CHRNA7CHRNB2CHRNA4AR | |
| SCHEMBL7507181 | 0.76 | CHRNA1 (0.52) | CHRNA1CHRNA7CHRNB2CHRNA4AR | |
| SCHEMBL7116775 | 0.68 | CHRNA1 (0.46) | CHRNA1CHRNA7CHRNB2CHRNA4GAA | |
| SCHEMBL7503498 | 0.68 | CHRNA1 (0.51) | CHRNA1CHRNA7CHRNB2CHRNA4AR | |
| SCHEMBL6358476 | 0.67 | CHRNA1 (0.57) | CHRNA1CHRNA7CHRNB2CHRNA4GAA | |
| SCHEMBL7504331 | 0.67 | CHRNB2 (1.00) | CHRNA1CHRNA7CHRNB2CHRNA4GAA | |
| SCHEMBL6357618 | 0.67 | CHRNA1 (0.50) | CHRNA1CHRNA7CHRNB2CHRNA4MAPK1 | |
| SCHEMBL7499966 | 0.65 | GABRA1 (0.39) | CHRNA1CHRNA7CHRNB2CHRNA4GAA | |
| SCHEMBL7498186 | 0.65 | CHRNB2 (0.55) | CHRNA1CHRNA7CHRNB2CHRNA4GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020028809-A1 | Heterocyclic compounds having effect of activating a4beta2 nicotinic acetylcholine receptors | SUNTORY LIMITED | 2002-03-07 | — | — | US | claimed |
| EP-1176141-A1 | HETEROCYCLIC COMPOUNDS HAVING EFFECT OF ACTIVATING NICOTINIC ACETYLCHOLINE $g(a)4$g(b)2 RECEPTOR | SUNTORY LIMITED (JP) | 2002-01-30 | — | — | EP | claimed |
| US-20020028809-A1 | Heterocyclic compounds having effect of activating a4beta2 nicotinic acetylcholine receptors | SUNTORY LIMITED | 2002-03-07 | — | — | US | disclosed |
| EP-1176141-A1 | HETEROCYCLIC COMPOUNDS HAVING EFFECT OF ACTIVATING NICOTINIC ACETYLCHOLINE $g(a)4$g(b)2 RECEPTOR | SUNTORY LIMITED (JP) | 2002-01-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020028809-A1 | Heterocyclic compounds having effect of activating a4beta2 nicotinic acetylcholine receptors | CHRNA2, CHRNA7, CHRNB2 | CHRNA1 6/4885CHRNA7 2/4885CHRNB2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.